Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
5.620
-0.270 (-4.58%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Editas Medicine
< Previous
1
2
Next >
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
June 09, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
June 06, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
May 18, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
May 16, 2023
Michelle Robertson to remain with Company until August 16, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
May 11, 2023
Company-sponsored webinar to be announced
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces First Quarter 2023 Results and Business Updates
May 05, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data
May 01, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
May 01, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
April 27, 2023
On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
April 13, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
March 08, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
February 22, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
February 15, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
January 25, 2023
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.
Via
MarketBeat
Topics
Workforce
Exposures
Layoff
Product Safety
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
January 19, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
January 09, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
December 06, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
December 01, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
November 17, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
November 02, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
October 26, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
October 13, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
3 Biotech Stocks Gaining Momentum
September 12, 2022
The headlines have been particularly good for a trio of small cap biotechs and it appears the momentum may have staying power.
Via
MarketBeat
Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
July 27, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates
July 26, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.